Therefore, the combination of NPM1 mutation and co-mutation of TET2 or IDH1/2 along with an APL-like immunophenotype identifies a distinct subtype of AML with a better prognosis. This evidence concerns the gene NPM1 and acute promyelocytic leukemia.